



RECEIVED
DEC 7 2001
TECH CENTER 1600/2900

1642

PATENT
Customer No. 22,852
Attorney Docket No. 5552.0953-04

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

)

#19 1/6/02
Today

Mathias FIBI et al.

)

Serial No.: 08/897,441

)

Group Art Unit: 1642

Filed: July 21, 1997

)

Examiner: K. Canella

For: *Erythropoietin (EPO) Peptides and
Antibodies Directed Against These*

)

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

RESPONSE TO OFFICE ACTION

In response to the Office Action of September 25, 2001, Applicants request consideration of the following arguments.

REMARKS

Claims 5-7, 9-12, and 14-23 are pending. Applicants gratefully acknowledge the Office's withdrawal of its previous rejections under 35 U.S.C. §§ 112, first and second paragraphs. The Office has reasserted its rejection of claims 6, 7, 11, and 17-21 for alleged obvious-type double patenting. Further, the Office currently rejects claims 5, 6, 11, 12, 17-20, and 23 under 35 U.S.C. § 102(b) and claim 10 under 35 U.S.C. § 103(a). Applicants address each outstanding rejection under its respective statutory section below.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com